Yukiko Nishimura, the president of ASrid, gave a presentation at World Orphan Drug Congress 2017
NATIONAL PATIENT ORGANIZATIONS
Making rare and intractable diseases an Asian health priority
- Japanese ‘Specified Disease Treatment Research Program’ and Orphan drug legislation to encourage orphan drug research
- J-Rare and ODOD (Open Discussion for Orphan Drug Discovery programs) to foster
rare disease identification, registries and diagnosis
- Connecting Asian rare disease stakeholders to accelerate the path to treatment
Yukiko Nishimura, President, ASrid